Serum visfatin levels in late pregnancy and pre‐eclampsia

Hu, Wensheng; Wang, Zhengping; Wang, Hanzhi; Huang, He‐Feng; Dong, Minyue

doi:10.1080/00016340801976012

Cited by 67 publications

(70 citation statements)

References 39 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is expressed in the placenta, foetal membranes and myometrium. It was reported that maternal plasma visfatin levels were significantly decreased in women with PE, and furthermore, its levels were correlated with severity of the disease [33]. However, another study reported that serum visfatin levels were higher in women with PE [34].…”

Section: Visfatinmentioning

confidence: 86%

Role of Biomarkers in Early Detection of Preeclampsia

Kar¹

2014

JCDR

View full text Add to dashboard Cite

Section: Visfatinmentioning

confidence: 86%

Role of Biomarkers in Early Detection of Preeclampsia

Kar¹

2014

JCDR

View full text Add to dashboard Cite

“…Sensitivity analysis was performed by omitting each study in turn and assessing the quality and consistency of the results. Begg's funnel plots and the Egger linear regression test were used to evaluate the publication bias (Hu et al, 2008). All reported P values are two-sided.…”

Section: Discussionmentioning

confidence: 99%

An elevated plasma level of visfatin increases the risk of myocardial infarction

Yang

Tao

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Visfatin, an adipocytokine involved in metabolic and immune disorders, plays an important role in the etiology of cardiovascular disease. Recent evidence has shown that an elevated plasma level of visfatin may increase the risk of myocardial infarction (MI), but individual published studies have shown inconclusive results. This study aimed to obtain a more precise estimate of the association between the plasma visfatin level and MI risk through a detailed meta-analysis of studies published in peer-reviewed journals. A literature search of articles published before May 1, 2013 was performed on the PubMed, Embase, Web of Science, and China BioMedicine databases. Crude standardized mean differences (SMDs) with 95% confidence intervals (CI) were calculated. Eleven case-control studies comprising 362 MI patients and 322 healthy controls were included. The meta-analysis revealed that an elevated plasma level of visfatin was associated with an increased risk of MI (SMD = 3.82, 95%CI = 2.67-4.98, P < 0.001). Further stratification based on the source of the controls showed that an elevated plasma 8587 Plasma visfatin level and MI risk ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 13 (4): 8586-8595 (2014) level of visfatin was significantly associated with increased risk of MI in both hospital-based and population-based studies (SMD = 4.12, 95%CI = 2.23-6.01, P < 0.001 and SMD = 3.65, 95%CI = 2.67-4.98, P < 0.001, respectively). No publication bias was evident in this meta-analysis. In conclusion, the current meta-analysis indicates that an elevated plasma level of visfatin increases the risk of MI. Therefore, plasma visfatin may be a promising biomarker for the diagnosis of MI.

show abstract

“…Higher visfatin levels were found in IUGR neonates compared with AGA counterparts, probably due to increased visceral adiposity or altered fetal development of adiposity in IUGR subjects [109,110].…”

mentioning

confidence: 95%